This invention is in the area of improved therapeutic combinations for and methods of treating selected retinoblastoma (Rb)-negative cancers and Rb-negative abnormal cellular proliferative disorders using particular topoisomerase inhibitors and specific cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. In one aspect, the improved treatment of select Rb-negative cancers is disclosed using specific compounds disclosed herein in combination with a topoisomerase I inhibitor.

The present invention is directed to compositions and methods targeting cells in a subject harboring conditions or at risk for conditions that would benefit from gas-based diagnostic and therapy. The present invention relates to the use of fluorochemical compositions and methods of delivery that result in retention of the fluorochemical composition and any bioactive agent, including gaseous substances, delivered in combination with the fluorochemical composition.

The present invention is directed to compositions and methods targeting cells in a subject harboring conditions or at risk for conditions that would benefit from gas-based diagnostic and therapy. The present invention relates to the use of fluorochemical compositions and methods of delivery that result in retention of the fluorochemical composition and any bioactive agent, including gaseous substances, delivered in combination with the fluorochemical composition.

The present invention is directed to compositions and methods targeting cells in a subject harboring conditions or at risk for conditions that would benefit from gas-based diagnostic and therapy. The present invention relates to the use of fluorochemical compositions and methods of delivery that result in retention of the fluorochemical composition and any bioactive agent, including gaseous substances, delivered in combination with the fluorochemical composition.

The present invention relates to compositions comprising a silicate and methods of use thereof. In particular, the compositions of the present invention are suitable for treating inflammatory conditions, cancer, bacterial and viral infections, and infected and uninfected wounds. The compositions of the present invention can also be useful in treating spinal cord injury, tissue remodeling, and promoting bone growth and repair.

Anti-microbial active particles, compositions and uses for inhibiting bacterial growth on surfaces or devices are described, with methods of making.

Anti-microbial active particles, compositions and uses for inhibiting bacterial growth on surfaces or devices are described, with methods of making.

Coatings comprising anti-microbial active particles are described, with methods of preparation and uses thereof.

Compounds are used in the reactivation of butyrylcholinesterase. Such compounds are useful in the treatment or prevention of intoxication with at least one organophosphorus nerve agent. Pharmaceutical compositions and kits include the compounds, and compounds per se.

Compounds are used in the reactivation of butyrylcholinesterase. Such compounds are useful in the treatment or prevention of intoxication with at least one organophosphorus nerve agent. Pharmaceutical compositions and kits include the compounds, and compounds per se.